Impact Biomedical Inc.
IBO NYSE
SEC CIK 1834105
Follow Impact Biomedical
Weekly email: filings, results
Revenue, last quarter
$21K
+16.7% vs same quarter last year
Net income
−$645K
+56.1% vs same quarter last year
EPS, diluted
−$0.08
+94.7% vs same quarter last year
Operating cash flow
$11K
+101.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$11.8M |
| FY24 | −$24.7M |
| FY23 | −$4.3M |
| FY22 | −$7.3M |
| FY21 | - |